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Abstract
Unicellular eukaryotes of the genus Leishmania are collectively responsible for a heterogeneous group of diseases
known as leishmaniasis. The visceral form of leishmaniasis, caused by L. donovani or L. infantum, is a devastating
condition, claiming 20,000 to 40,000 lives annually, with particular incidence in some of the poorest regions of the
world. Immunity to Leishmania depends on the development of protective type I immune responses capable of
activating infected phagocytes to kill intracellular amastigotes. However, despite the induction of protective
responses, disease progresses due to a multitude of factors that impede an optimal response. These include the
action of suppressive cytokines, exhaustion of specific T cells, loss of lymphoid tissue architecture and a defective
humoral response. We will review how these responses are orchestrated during the course of infection, including
both early and chronic stages, focusing on the spleen and the liver, which are the main target organs of visceral
Leishmania in the host. A comprehensive understanding of the immune events that occur during visceral
Leishmania infection is crucial for the implementation of immunotherapeutic approaches that complement the
current anti-Leishmania chemotherapy and the development of effective vaccines to prevent disease.
Background
Leishmania is a genus of kinetoplastid eukaryotes whose
life-cycle relies on continuous shuttling between a mam-
malian host and an insect vector. These protozoans have
a digenetic lifestyle, undergoing dramatic morphological
changes to ensure adaptation and survival in either host.
Within the gut of the sandfly vector, Leishmania endures
as extracellular, flagellated and motile promastigotes.
Conversely, in mammalian hosts, parasites survive and
replicate inside host’s phagocytes as non-motile, round
and obligate intracellular amastigotes. The continuous
replication of amastigotes inside macrophages leads to
apoptotic cell death of the host cell. The ingestion of
apoptotic bodies and membrane blebs containing viable
parasites by neighboring phagocytes allows a silent
propagation of the infection [1].
More than 30 species of Leishmania have been identified,
of which about 20 are human pathogens. The leishmaniases
are divided into three medical conditions that involve cuta-
neous, mucocutaneous or visceral pathology. Virtually, all
the mortality associated with the leishmaniases results from
visceral disease. Due to the remote location of many
visceral leishmaniasis (VL) endemic areas, the degree of
under-reporting is severe. Conservative assumptions esti-
mate the annual incidence at 400,000 cases, with about
20,000 to 40,000 associated deaths [2]. The primary VL en-
demic foci are located in the Indian sub-continent and East
Africa, accounting for approximately 90 % of all cases [2].
L. donovani causes VL in Asia and East Africa, while L.
infantum accounts for visceral disease in the Mediterranean
basin and South America [3].
Visceral leishmaniasis has an asymptomatic incubation
period of variable duration and early symptoms include
intermittent fever, malaise and shivering. Overt disease
manifests by striking splenomegaly, accompanied or
not by hepatomegaly. In cases of concurrent VL and
Acquired Immunodeficiency Syndrome (AIDS), spleno-
megaly may be absent. The hyperplasia of the reticulo-
endothelial system is accompanied by wasting and
pallor of the mucous membranes [3–5]. Mononuclear
phagocytes in the spleen, liver, bone marrow and lymph
nodes appear heavily parasitized, but lymphocyte infil-
tration is usually scarce. In the spleen, atrophy of the
white pulp is common, with loss of the architectural
organization of lymphoid structures. Plasma cells are
abundant in the spleen, and probably associated with
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the occurrence of polyclonal hypergammaglobulinemia.
Anemia, thrombocytopenia and neutropenia are fre-
quent and reflect both splenic sequestration and sup-
pression of bone marrow function. Immune complexes
are present, sometimes associated with nephritis, pro-
teinuria and microscopic hematuria [3–6]. At advanced
stages, thrombocytopenia along with prothrombin de-
pletion leads to severe mucosal hemorrhage. Jaundice
and ascites also occur at advanced disease. Secondary
infections, particularly tuberculosis and pneumonia, be-
come common and are frequent causes of death [5].
Immunity to Leishmania has long been known to depend
on the development of type I immune responses character-
ized by initial production of Interleukin-12(IL-12) by
antigen-presenting cells (APCs) that induce Interferon-
γ(IFN-γ)-secreting Th1 T cells [7]. These, in turn, will
induce the activation of the macrophage’s microbicidal
mechanisms; in particular they induce the production of ni-
tric oxide (NO) and reactive oxygen species (ROS), which
are highly effective in killing intracellular amastigotes [8].
However, early studies noticed that VL progresses even in
the presence of detectable levels of T helper-1 (Th1) cyto-
kines, whose action is neutralized by immunosuppressive
factors, such as IL-10 [9–11].
Here, we will review the immune events occurring in
visceral organs, focusing on the spleen and the liver, dur-
ing the acute and chronic stages of VL. By highlighting
the main immune parameters associated with parasite
persistence vs. parasite elimination, we aim to provide a
concise picture of the immunology of VL that may help
in the development of new therapeutic strategies.
Review
Studying the immunology of visceral leishmaniasis:
animal models and human patients
Due to the intrusive procedures required to study in-
fected organs in VL patients, the bulk of the knowledge
concerning the regulation of immunity during VL has
been obtained from mouse models [12]. In murine VL,
the terms resistance and susceptibility refer to the ability
of the host to rapidly control parasite growth. Indeed,
susceptible strains such as the Balb/c develop a life-long
chronic infection, which unlike humans is not fatal to
the host. Most studies in mice are based on intravenous
or intraperitoneal injection of a high dose of parasites,
hence bypassing the early events on the skin and para-
site navigation to the viscera [13]. Some comparative
studies suggest that the parasite dose and inoculation
route influence the kinetics of parasite colonization of
the viscera and the ensuing immune response [14, 15].
Acknowledging these limitations, researchers are starting
to employ alternative animal models of the disease to
perform in-depth immunologic studies, such as the ex-
tremely susceptible Syrian hamster model, through
sand-fly-mediated parasite inoculation [16]. Also, the re-
cent use of rhesus macaques as models of VL takes ad-
vantage of the close phylogeny between humans and
non-human primates and provides a window to the early
events after infection which are silent in humans and
hence not accessible [17, 18].
In mice, VL provides a clear example of organ-restricted
immunity. In the liver, infection is self-resolving, in a man-
ner that is dependent on the development of T cell-
mediated immunity and formation of granulomas [19]. In
contrast, in the spleen the immune system fails to clear
parasites and instead, a lifelong chronic infection persists
associated with immunopathology [20]. The compartmen-
talized immune responses clearly observed in murine VL
are not evident in human patients, where infection is pro-
gressive and varying degrees of parasite load are observed
in the viscera [21]. Also, in the Syrian hamster, parasites
grow unimpaired in the spleen, liver and bone marrow
(BM), until animal demise [22]. Finally, in our recent study
in L. infantum-infected rhesus macaques, we observed a
progressive increase in the parasite load in visceral organs
as the infection advanced toward the chronic phase
(8 months) [17]. Nevertheless, the compartmentalized im-
mune response observed in mouse VL has been instrumen-
tal in defining the immune networks that dictate parasite
elimination vs persistence during visceral Leishmania infec-
tion. We will address these events in the following sections.
Mechanisms underlying the control of hepatic infection in
mice
Liver resident Kupffer macrophages harbor most parasites
after intravenous injection of mice with L. donovani or L.
infantum [23, 24]. Kupffer cells have reduced innate cap-
acity to kill intracellular Leishmania and hepatic parasite
burden increases rapidly during the first weeks [25, 26].
Restriction of liver parasite numbers parallels the assembly
of inflammatory structures, known as granulomas, consti-
tuted by a central core of fused and parasitized Kupffer
cells and an outer cuff of motile lymphocytes and variable
amounts of other immune cells [24, 27, 28]. Granulomas
allow the local concentration of inflammatory cytokines
that in turn efficiently activate the leishmanicidal mecha-
nisms of Kupffer cells [29]. The kinetics of granuloma
maturation during experimental infection of mice with L.
donovani has been dissected in detail [27, 29, 30]. Interest-
ingly, Kupffer cells exposed to the inflammatory environ-
ment during infection, but not directly infected by the
parasite, appear activated a few hours after parasite inocu-
lation and play a crucial role in initiating the protective
response [31], by secreting several chemokines and cyto-
kines that recruit immune populations, including mono-
cytes, neutrophils and invariant natural T killer (iNKT)
cells [32–34]. INKT cells, in particular, play a major role in
coordinating initial granuloma formation [35]. Via their
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invariant T-cell receptor (TCR), iNKT cells recognize
CD1d-bound lipophosphoglycan (LPG), the most abun-
dant surface glycolipid of Leishmania spp., triggering early
production of IFN-γ [36]. Additionally, iNKT cells rapidly
secrete several cytokines upon activation, including C-X-C
motive chemokine-10 (CXCL10), which attracts T cells
and promotes maturation of granulomas [34, 35, 37].
However, the role of iNKT cells during VL is unclear, as
their activation with selective ligands was contradictorily
associated to disease amelioration or aggravation in inde-
pendent studies [38, 39]. It is possible that these cells are
important in the orchestration of the initial response after
infection, but their chronic activation is detrimental to the
host [39].
By one week after infection, T cells are recruited to the
granuloma and eventually become the predominant im-
mune cell type [40]. Given the low level of innate para-
site killing in the early stages of infection in the liver, it
has long been assumed that the majority of parasite-
specific T cells were primed in the spleen and subse-
quently migrated to the liver, guided by chemotactic
gradients [30]. Nevertheless, a recent study demon-
strated that specific CD4 T cells can be primed in the
liver and suffice to confer hepatic immunity [41]. Both
CD4 and CD8 T cells appear indispensable for the devel-
opment of mature granulomas [40]. Two-photon im-
aging revealed that antigen presentation to CD8 T cells
is restricted to Kupffer macrophages [42], whereas CD4
T cells may be activated by both Kupffer cells and some
granuloma-associated dendritic cells (DCs) [13, 29].
A number of cytokines play critical roles in granu-
loma development and parasite killing. IL-12 is pro-
duced by activated Kupffer macrophages and induces
IFN-γ by granuloma-associated lymphoid cells [43]. In
turn, IFN-γ maximizes the leishmanicidal capacity of
Kupffer cells [13]. Arguably, the most important sol-
uble factor for granuloma development and hepatic
control of Leishmania infection is Tumor Necrosis
Factor (TNF), which plays a crucial role in coordinat-
ing the assembly and maturation of granulomas [20].
In the absence of TNF, parasite growth in the liver
proceeds unimpaired during the first weeks due to
completely absent granuloma formation. However,
later in infection (6–8 weeks) there is an abrupt
assembly of granulomas causing rapid death due to
fulminant hepatic necrosis [44, 45]. Additionally,
lymphotoxin-α, a TNF-related cytokine, promotes the
recruitment of leukocytes from the perivascular space
to the sinusoidal areas, where infected Kupffer cells
reside [46].
Granulomas attain full maturation by 2–4 weeks after
infection and hepatic parasite burden rapidly declines up
to 8 weeks post-infection [27]. Importantly, sterile im-
munity in the liver is not achieved. However, the
presence of a residual parasite population is thought to
incite a small but enduring immune response that pro-
vides long-term immunity to reinfection [13].
Early events in the spleen during visceral Leishmania
infection
The spleen is the body’s largest blood filter. Splenic macro-
phages are strategically placed to remove any exogenous
particle or pathogen that enters the spleen through the
blood stream [47]. Following intravenous injection of L.
donovani, about 95 % of the parasites are phagocytized by
three distinct splenic populations; red pulp macrophages,
marginal zone macrophages (MZM) and marginal metallo-
philic macrophages (MMM) [48]. Unlike liver Kupffer cells,
macrophage populations of the spleen demonstrate a re-
markable innate capacity to kill the parasite. Indeed, it is es-
timated that 50 % of the initial parasite inoculum is killed
by macrophage populations of the marginal zone within
the first 24 hours after infection [48]. For both MZMs and
MMMs this was shown to depend on the recruitment of
the Interferon Regulatory Factor (IRF)-7 to parasite-
containing phagosomes and may involve leishmanicidal
mechanisms independent of NO [49].
A few hours after mice infection, mature DCs appear
in T cell areas at the periarteriolar lymphoid sheaths
(PALS) and produce IL-12 to initiate protective T cell re-
sponses [48, 50, 51]. Interestingly, priming DCs do not
contain viable parasites, which led to the notion that
protective T cell responses are induced by DCs activated
in a bystander manner, hence resembling the early
events in the liver mediated by bystander Kupffer cells
(Fig. 1) [52, 53]. It is not clear how bystander DCs ac-
quire parasite antigens for T cell priming. DCs may
phagocytize parasite debris present in the splenic mar-
ginal zone or ingest macrophages containing digested
parasites [13]. In mice infected with L. donovani, CD4 T
cell activation can be detected in the first day after infec-
tion and the pool of parasite-specific splenic CD4 T cells
increases several fold during the first weeks contributing
to splenomegaly [20, 54].
In CD4 T cells, IL-12 signaling leads to nuclear trans-
location of Signal Transduction and Activator of
Transcription-4 (STAT-4) resulting in induction of the
transcription factor T-box transcription factor-21 (T-bet)
and upregulation of IL-12 receptor (IL-12R) to prime for
Th1 differentiation. T-bet, in turn, induces the cardinal
Th1 cytokine IFN-γ that through autocrine signaling acti-
vates STAT-1 and further stabilizes the Th1 lineage [55].
There is substantial evidence indicating that all the com-
ponents involved in Th1 differentiation are necessary for
an effective response against visceral Leishmania [56–59].
Shortly after infection, splenic DCs are also capable of
producing other members of the IL-12 family, including
IL-23p19 [60], which may pair with IL12p40 to form
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biologically active IL-23 [61]. Along with additional cyto-
kines present in the VL spleen, such as the Transforming
Growth Factor-β (TGF-β), IL-6 or IL-1β; IL-23 promotes
the differentiation of Th17 cells from naïve CD4 T cells
[55]. Recent evidence suggests an important protective
role for Th17 cells during VL (Fig. 1). Mice deficient for
the IL17 receptor A (IL17RA) were more susceptible to
L. infantum infection, exhibiting decreased numbers of
splenic IFN-γ-producing CD4 T cells. Furthermore, IL-
17A acts synergistically with IFN-γ to potentiate NO
production in infected macrophages [62]. These studies
in mice are supported by observations in human pa-
tients. For instance, analysis of cytokine responses in
peripheral blood mononuclear cells (PBMCs) from
symptomatic and asymptomatic VL patients revealed
that the expression of Th17 cytokines was strongly
associated with the asymptomatic state [63, 64]. Also,
another study noticed negligible transcript levels of
Th17-associated cytokines or transcription factors in
splenic tissue from patients with active disease [65].
Interestingly, IL-17A appears to play a host-detrimental
role during infections by cutaneous Leishmania species
[66]. During parasite development in the sand-fly vector,
Leishmania produces extracellular vesicles (also known
as exosomes) which accumulate in the midgut and be-
come part of the inoculum injected by the fly during
feeding. By exacerbating the inflammatory response, par-
ticularly through the induction of IL-17A, exosomes
cause larger lesion size and longer footpad swelling [67].
It would be interesting to explore whether exosomes
described in visceral Leishmania species [68], similarly
induce an exacerbation of the immune response in the
skin or instead down regulate inflammation to allow a
silent navigation to the viscera.
CD8 T cell-mediated immunity has been compara-
tively less studied than the CD4 T cell response during
Fig. 1 The immunologic environment in the spleen during visceral leishmaniasis. The picture aims to summarize the main host-protective
responses occurring during VL in the spleen, as well as the major immune networks that promote parasite persistence (top half). Protective
responses in the spleen are initiated by DCs exposed to parasite products, but not productively infected by Leishmania (bystander DCs).
These secrete cytokines such as IL-12 or IL-23 that guide the differentiation of Th1 or Th17 cells, respectively, which, in turn, will produce
IFNγ, TNF or IL-17 that maximize the capacity of infected macrophages to produce NO and ROS. In parallel, naïve CD8 T cells are primed
by DCs in the presence of IL-12 and type I IFNs and differentiate into effector cells that further contribute to the protective response by
producing IFNγ and TNF. Effector CD8 T cells may also degranulate perforin and granzymes and kill infected cells, although it remains
unclear whether cytotoxic mediators play any protective role during VL. In contrast, in infected DCs the parasite hijacks the capacity of the
cell to initiate protective responses (the mechanisms employed by Leishmania to subvert signaling pathways and impair host cell function
fall outside the scope of this review and the reader is referred to recent reviews [167, 168]). The combined secretion of cytokines such as
IL-12, IL-27 and IL10 by infected DCs leads to the differentiation of Tr1 cells that simultaneously produce IFN-γ and IL-10 and decrease the
leishmanicidal capacity of the macrophage. In parallel, parasite persistence and possibly suppressive cytokines lead to the exhaustion of
specific CD8 T cells, by upregulating the expression of inhibitory receptors such as PD-1, LAG-3 or additional unidentified receptors. These
cells perform very limited effector function hence decreasing the capacity of the host to fight the parasite
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VL [69–71]. The expansion of splenic CD8 T cells after
infection is impressive and may reach 10-fold within a
2 month period [20, 72]. CD8 T cells respond to IL-12
and type I IFNs by upregulating the T-bet and Eomeso-
dermin (Eomes). These promote the expression of type I
cytokines such as TNF or IFN-γ and cytotoxic molecules
such as granzymes and perforin which allow CD8 T cells
to perform effector function [73]. There is sustained evi-
dence pointing to an important role of CD8 T cell-
derived IFN-γ in the activation of infected macrophages
to control parasite growth [70, 71, 74]. Less clear is
whether CD8-mediated cytotoxicity plays any protective
role (Fig. 1). Some studies in mice demonstrate that
parasite-specific cytotoxic T lymphocytes (CTLs) gener-
ated during infection are capable of killing infected cells
ex vivo [70, 74, 75], via mechanisms relying on the per-
forin/granzyme and Fas/FasL pathways [70]. However, it
is not clear whether the parasite is killed concomitantly
with the demise of the host cell. In vitro experiments in-
dicate that parasites remain viable after CD8-mediated
host cell lysis, but are eventually killed after infecting
neighboring macrophages pre-activated with CD8-
derived IFN-γ [76]. These observations suggest that the
cytotoxic and cytokine-secreting functions of CTLs col-
laborate for efficient parasite killing, but such mechan-
ism has so far not been demonstrated in vivo. The role
of CD8 T cell effector function has been studied with
more detail in infections with cutaneous Leishmania
species [77]. In mouse models of CL and human CL pa-
tients, the current paradigm indicates that CD8 T cells
producing IFN-γ contribute to the protective response
against the parasite while CD8-mediated cytotoxicity
leads to tissue pathology and promotes skin ulceration
[78–82]. Whether a similar dichotomy in the effector
functions of CD8 T cells is operative in VL remains un-
known and is a matter of great interest in future studies.
In mice, after the initial period of parasite elimination
by splenic macrophages, the parasite population is main-
tained at a constant size throughout the following
two weeks, suggesting that parasite replication is bal-
anced by parasite killing [19]. While able to control in-
fection, the immune response appears to be far from
optimal, as it cannot eradicate the parasite. By the third
week after infection, parasite load in the spleen starts to
increase slowly, signaling the onset of the chronic phase.
By this time, infection is starting to resolve in the liver
[19]. In the following sections, we will review the main
immune networks responsible for parasite persistence in
the spleen during chronic VL.
Chronic visceral leishmaniasis: regulatory cytokines
Mice deficient in the immunosuppressive cytokine IL-10,
or in which IL-10 signaling is blocked, are highly resistant
to L. donovani infection [83, 84]. IL-10 is found in elevated
levels in the serum, splenic aspirates, lymph nodes and
bone marrow of VL patients [65, 85, 86] and is produced
after Leishmania antigen stimulation of whole blood cul-
tures from patients with active disease, but significantly de-
creases after drug cure [87]. Neutralization of IL-10
augments IFN-γ production in whole blood assays and pro-
motes amastigote clearance in cultured splenic cells from
VL patients [87, 88]. Together, all these pieces of evidence
led to the conclusion that IL-10 is the major mediator of
the immunological defects observed in the spleen during
chronic VL [89, 90].
IL-10 is a general suppressive cytokine with a range of
anti-inflammatory effects in several immune lineages
[91]. During VL, IL-10 deactivates the leishmanicidal
mechanisms of the macrophage and down regulates the
expression of co-stimulatory molecules and MHC ex-
pression [89, 92, 93]. It also decreases the production of
IFN-γ in T cells [87, 94] and inhibits DC migration to T
cell areas [95].
IL-10 can be produced by multiple immune line-
ages [91, 96]. During VL, several cell types have
been identified as sources of IL-10, including CD4
and CD8 T cells, B cells, NK cells, macrophages and
DCs [53, 85, 97–100]. A major topic of interest in
the past decade has been the identification of the
relevant sources of IL-10 during VL. The best avail-
able evidence points to conventional IFN-γ-secreting
Th1 cells as the most relevant source of pathological
IL-10 during chronic experimental and human VL
(Fig. 1) [17, 53, 85, 101, 102]. In mice, splenic CD4
T cells producing both IFN-γ+ IL-10+(sometimes
denoted as type I regulatory T cells, Tr1) can be de-
tected already at two weeks after parasite infection
and attain a plateau by one month, representing 2 to
5 % of the total splenic CD4 T cell pool [53, 101].
A matter of upmost interest is to decipher the mech-
anisms underlying the regulatory switch that results in
the induction of the IFN-γ+ IL-10+double producer
CD4 T cells. Recent studies are unveiling a cytokinic
network that works to maintain the suppressive envir-
onment during chronic VL. One study, employing
splenocytes from human VL patients evidenced a role
for T cell-derived IL-21 and myeloid cell-derived IL-27
in the induction of IL-10 in CD4 T cells [65]. More-
over, recent data points to a crucial role for DCs in
promoting the regulatory switch in CD4 T cells (Fig. 1)
[53, 101]. Indeed, DC-derived IL-27 and IL-12 appear
to be involved in the induction of IL-10 in CD4 T cells
[53, 101]. Interestingly, the suppressive-promoting
capacity is restricted to infected DCs [53] and DC de-
pletion between the third and fourth week after infec-
tion reduces pathology and enhances resistance to
infection [101]. Finally, IL-10 signaling may contribute
to additional IL-10 and IL-27 secretion by the infected
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macrophage, to continuously fuel this suppressive loop
[65, 103]. Expression of IL-10 by Th1 cells is a widespread
phenomenon that ensures a tight control over exces-
sive activation that may cause pathology [96, 104].
During infections with the apicomplexans Plasmo-
dium or Toxoplasma, the emergence of IL-10+ IFN-γ+
CD4 T cells is required to limit excessive pathology
[105, 106]. Even during VL some evidence suggests
that IL-10 may be host protective; particularly, in
regulating a detrimental inflammatory response in the
liver. Indeed, the extensive hepatic necrosis accom-
panying L. donovani infection in TNF-deficient mice
may result from a concomitant defect in IL-10 induc-
tion [13]. Likewise, the severe hepatic pathology that
follows L. donovani infection in IL27R−/− mice involves
CD4 T cells and may result from curtailed IL-10 induc-
tion [107].
The suppressive role played by DCs during chronic VL
is not limited to the induction of Tr1 cells. Indeed, early
work evidenced the expansion of a CD11low CD45RBhi
DC population during L. donovani infection in mice that
dampened T cell responses and induced antigen-specific
tolerance in vivo [108]. The transfer of these CD11clow
DCs to DC-depleted and infected mice was able to restore
splenomegaly and parasite burden to levels present in
non-depleted mice, via a mechanism that did not involve
the induction of Tr1 cells [101]. Finally, a recent study
demonstrated that the early inflammatory milieu during
VL promotes the activation of IRF-5 in DCs, which leads
to upregulation and stabilization of the transcription fac-
tor Hypoxia Inducible Factor-1α (HIF-1α). HIF-1α, in
turn, promotes the secretion of IL-10 by DCs, while limit-
ing IL-12, which results in delayed expansion of specific
CD8 T cells and their limited effector function, thus fur-
ther supporting the suppressive role of DCs and IL-10
during VL (Fig. 1) [109].
Whilst much less studied than IL-10, TGF-β is another
suppressive cytokine that has been linked with parasite
persistence in VL [90, 110, 111]. Additionally, mice re-
sistant to L. infantum infection become significantly
more susceptible when injected with a viral vector ex-
pressing TGF-β [110].
Chronic visceral leishmaniasis: T cell exhaustion
Chronic infections are characterized by a prominent im-
pairment of T cell function, known as T cell exhaustion,
which precludes an effective response in the long term
[112]. Exhaustion proceeds progressively, paralleling the
increase in pathogen burden [112]. Some functions, such
as cytotoxicity, IL-2 production or proliferation are lost
initially. Severe exhaustion is characterized by an inability
to produce TNF, IFN-γ or to degranulate [113]. Apoptotic
deletion is usually the final fate of an exhausted T cell.
Nevertheless, exhausted T cells are capable of long-term
survival, if their specific antigen remains present [112].
Evidence has convincingly linked the occurrence of T cell
exhaustion with progressive and sustained expression of
inhibitory receptors on effector T cells [114]. These in-
clude programmed death-1 (PD-1), cytotoxic T lympho-
cyte antigen-4 (CTLA-4) or lymphocyte-activation gene-3
(LAG-3) [112, 115, 116]. These receptors act by inhibiting
T cell activation, thus precluding optimal effector func-
tion. T cell exhaustion was initially noticed over a decade
ago in models of chronic viral infections [117, 118], but
recent work unveiled a similar paradigm during chronic
protozoan infections [119].
In mice infected with L. donovani, splenic CD8 Tcells ex-
hibit signs of functional exhaustion by the third week after
infection, and severe functional impairment is evident after
the fourth week, with abrogated production of IFN-γ, TNF,
IL-2 and granzyme B (Fig. 1) [120]. Exhaustion is paralleled
by increased expression of PD-1 in CD8 T cells and its lig-
and PD-L1 in splenic DCs. Treatment with an antibody
blocking the PD-1/PD-L1 interaction rescued the function-
ality of parasite-specific effector/memory CD8 T cells,
resulting in lower splenic parasite burden [120]. Interest-
ingly, the recovery of CD8 T cell effector function after α-
PD-1 treatment was only partial [120], suggesting that
additional inhibitory receptors may contribute to the func-
tional attrition of CD8 T cells during VL. In agreement,
mice treated with a CTLA-4 blocking mAb 1 day after in-
fection demonstrate significantly lower parasite burden by
1 month post-infection, consistent with the timing of CD8
Tcell exhaustion [121, 122]. The relevance of these findings
in mice has been confirmed in human VL patients, whose
splenic CD8 T cells similarly exhibited functional impair-
ment and augmented expression of PD-1 and CTLA-4
[123]. Contrasting with the wealth of evidence demonstrat-
ing CD8 T cell exhaustion, in CD4 T cells the phenomenon
has been far less studied and is less understood [112]. In
chronic canine VL, splenic CD4 T cell exhaustion is less se-
vere than CD8 exhaustion and appears only in aggravated
clinical stages of the disease [124].
Suppressive cytokines, such as IL-10 and TGF-β, have
been consistently linked with T cell exhaustion in viral
infections and cancer [125]. For instance, TGF-β directly
enhances PD-1 expression in CD8 T cells [126]. Due to
the elevated levels of these cytokines in the VL spleen it
would be interesting to explore how these cytokines in-
fluence T cell exhaustion during VL and whether their
blockade leads to an amelioration of the functionality of
effector T cells (Fig. 1).
Chronic visceral leishmaniasis: loss of splenic lymphoid
architecture
The most striking clinical feature of both human and
experimental VL is the impressive splenomegaly [30].
Concomitant with increased organ mass and size, a
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number of changes in the splenic microarchitecture
occur [20]. These include disorganization of the white
pulp, hypertrophy of the red pulp and disruption of the
marginal zone. In the white pulp, germinal centers
(GCs) disappear, and the PALS collapses [127]. Neovas-
cularization is also prominent in both red and white
pulp [128, 129].
In mice, the structural changes in the spleen start as the
infection enters the chronic phase (around 3 to 4 weeks
post-inoculation) [30]. Disorganization of the PALS is me-
diated by TNF and results mainly from the loss of gp38+
stromal cells. These are crucial for establishment and
maintenance of the PALS by producing the chemokines
Chemokine (C-C motif) Ligand-19 (CCL19) and CCL21,
which attract naïve and memory T cells [95, 130, 131].
Concomitant with the disassembly of the PALS, an exten-
sive remodeling of the splenic marginal zone also occurs,
characterized by depletion of the MZM population [132].
Again, TNF appears to mediate the loss of MZMs,
through a mechanism that is not clearly elucidated but
may involve a direct apoptotic effect [132]. It is intriguing
to note that TNF, the crucial cytokine responsible for the
maturation of protective granulomas in the liver, is simi-
larly the major factor responsible for the histopathological
sequelae of chronic infection in the spleen [13].
A final significant alteration in the lymphoid architec-
ture of the spleen during chronic VL is the loss of fol-
licular dendritic cells (FDCs), leading to loss of GCs and
B cell follicles, which become occupied by parasitized
macrophages and plasma cells [13]. The structural
changes that lead to loss of splenic lymphoid architec-
ture during chronic VL disrupt cell-cell interactions that
are crucial for effective immune responses, thus contrib-
uting to the suboptimal responses during chronic VL.
For instance, the deletion of FDCs and concomitant
disorganization of GCs impedes the long-term interac-
tions between B cells and T follicular helper cells (Tfh
cells) that are necessary for the production of specific
antibodies capable of neutralizing the parasite [133].
Antibodies, B cells and T follicular helper cells in visceral
leishmaniasis
Experimental work performed over the past decades
led to a prevailing view that considers B cells and
antibodies of minimal importance for the protective
immunity during VL. Indeed, hypergammaglobuline-
mia has long been recognized as one of the cardinal
signs of VL, correlates positively with disease severity
and decreases upon drug cure [134–138]. Early stud-
ies also demonstrated that most of the circulating
IgGs are not parasite-specific, but instead result from
polyclonal B cell activation [139, 140]. Indeed, auto-
antibodies are a recurrent finding in VL patients
[141–143], frequently associated with proliferative
glomerulonephritis [144].
In our recent study, employing a non-human primate
model of VL, hypergammaglobulinemia was established
early after infection and persisted during the chronic phase.
Yet, the production of Leishmania-specific IgG was short-
lived and decreased at chronic infection, implying that most
antibodies produced are not specific for the parasite [17].
Analyzing the splenic B cell population we observed the ex-
pansion of memory B cells expressing CD27 after infection
that contracted at the chronic phase, hence closely follow-
ing the production of specific antibodies. We further ob-
served the persistent expansion of a splenic B cell
population with the atypical CD21−CD27− phenotype that
appeared responsible for the non-specific hypergammaglo-
bulinemia (Fig. 2) [17]. These observations incited us to
explore the dynamics of T follicular helper cells (Tfh cells)
in the spleen of rhesus macaques infected with L. infantum.
Tfh cells are a CD4 T cell helper subset specialized in
coordinating GC reactions and providing crucial help to B
cells in the production of high affinity antibodies [145]. In-
deed, we observed the expansion of a splenic Tfh popula-
tion in the first few weeks following parasite inoculation.
Tissue imaging further evidenced that Tfh cells were able
to infiltrate B cell follicles and GC during the acute phase.
However, Tfh cells were mostly absent from the spleen at
the chronic phase, hence paralleling the decline in CD27+
memory B cells and specific IgG [17]. Thus, our study in
non-human primates suggests that the inability to maintain
a sustained Tfh response during the chronic phase of infec-
tion may underlie the defects in the humoral response
during VL (Fig. 2). Thus, it will be important to decipher
the immune mechanisms behind this failure to maintain
Tfh cells. One possibility may relate to the existence of a
strong Th1-polarizing environment in the spleen during
VL, with induction of expression of T-bet in CD4 T cells
that directly represses the expression of the Tfh master
transcription factor B cell lymphoma-6 (Bcl-6) (Fig. 2)
[146]. Furthermore, the destruction of FDC networks and
loss of GCs that occurs during VL, may also preclude a
sustained Tfh differentiation and preclude their effector
function.
During chronic VL, amastigotes are exposed to anti-
bodies when they egress from heavily infected macro-
phages to infect new ones. The view that antibodies are
detrimental to the host is supported by the observation
that, when ingested by macrophages, IgG-opsonized
amastigotes promote IL-10 secretion and inhibit IL-12
production [135, 147, 148]. However, ligation of FcγRs
on the surface of macrophages and DCs may lead to
pro- or anti-inflammatory outcomes, depending on the
identity of the Fc receptors activated, IgG subclass or
cell type [149, 150]. For instance, one study demon-
strated that parasite-specific IgG is required for efficient
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L. major uptake and IL-12 production by DCs, suggest-
ing that FcγR-mediated uptake has contrasting outcomes
in DCs and macrophages [151]. Also, in a model of co-
infection of L. amazonensis and L. major in mice, it was
shown that resolution of the lesion required specific
antibody that was able to enhance the microbicidal
mechanisms in the macrophage by promoting ROS pro-
duction [152, 153]. As such, the role of antibodies and
Fc receptors during Leishmania infections is more com-
plex than previously appreciated, with the outcome of
FcγR ligation being clearly context-dependent.
Furthermore, the role of antibodies as regulators of
the inflammatory response is not necessarily detri-
mental to the host. While B cell-deficient mice resolve
L. donovani infection more rapidly than WT mice,
such increased resistance comes at the cost of hepatic
pathology. However, administration of immune serum
to infected B cell-deficient mice alleviates pathology
without decreasing the efficiency of hepatic parasite
clearance, suggesting a tissue-protective role for anti-
bodies [154].
Even conceding that parasite opsonisation by specific
IgG is deleterious for the host, there are alternative
mechanisms through which antibodies may contribute
to the protective response against Leishmania; for
instance by neutralizing parasite virulence factors. An
illustrative example comes from the intracellular bac-
teria Listeria monocytogenes. A monoclonal antibody
against listeriolysin, the pore-forming toxin of L. mono-
cytogenes, was capable of blocking bacterial replication
inside macrophages and provided resistance to infec-
tion in mice [155, 156]. Antibodies against Leishmania
virulence factors, such as the metalloprotease gp63,
have been detected in the sera of VL patients [157], but
it is not clear whether they are capable of neutralization
or play any protective function. As such, it is imperative
to identify antibodies with neutralizing capacity and to
evaluate whether their administration is capable of
Fig. 2 Dysfunctional humoral response during visceral leishmaniasis. The picture summarizes the sequence of events that lead to a suboptimal
humoral response during visceral leishmaniasis, based primarily on data from our recent study in non-human primates compounded with evidence from
additional studies. (1) Shortly after parasite inoculation, B cells are activated in a non-specific manner by soluble parasite products that act as B cell mitogens
as well as by inflammatory mediators generated during the response to infection. (2) As a result, B cells with the atypical CD21− CD27− phenotype expand
and eventually give rise to plasmablasts that produce copious amounts of immunoglobulin leading to the occurrence of hypergammaglobulinemia. (3)
Some B cells appear to be activated in a specific manner via their BCR and follow the follicular pathway where they engage in cognate interactions with
pre-Tfh cells. (4) If these interactions are productive, both cell types proceed to form a germinal center where Tfh cells promote affinity maturation of B cell
for their specific antigen and direct the selection of the B cells clones with the highest affinity. B cells then exit the germinal center as high-affinity CD27+
memory B cells and plasma cells that produce antibodies with high affinity for the parasite. (5) However, the germinal center response is not sustained
during the chronic phase of infection accompanying the decreasing numbers of Tfh cells. A strong Th1-polarizing environment is established in the spleen
during VL, with high levels of expression of T-bet in CD4 T cells. Given that T-bet and the Tfh master transcription factor, Bcl-6, mutually repress each other’s
expression, it is reasonable to speculate that the inflammatory environment during VL is unfavourable for the sustained differentiation of Tfh cells
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modifying the course of the disease to the benefit of the
host.
Rather than considering the role of antibodies solely as
pathological or irrelevant, it is perhaps wiser to acknow-
ledge that these molecules may play both protective and
non-protective roles during VL.
Conclusions
The fight against the Neglected Tropical Diseases has
received worldwide attention after the recent attribution of
the 2015 Nobel Prize in Physiology or Medicine to William
Campbell and Satoshi Ōmura for their development of a
novel therapy against infections caused by roundworm
parasites. Given its deadly and poverty-promoting features,
control of visceral leishmaniasis should be given a high
priority by policy makers of public health worldwide [158].
In 2007, the World Health Assembly delineated a proposal
to drastically reduce the burden associated with the leish-
maniases in the following years. By 2020, it is expected to
identify and treat all cases of VL in the endemic regions of
Africa, Europe and Americas and to reduce the prevalence
below 1/10,000 in the endemic districts of the Indian sub-
continent [159]. Such ambitious plan requires effective and
affordable drugs. Unfortunately, all the available anti-Leish-
mania medicines suffer from more or less severe side-
effects. In this context, immunotherapeutic approaches
may help to restore immune function, potentially decreas-
ing the dose of drug administered, while maintaining drug
efficacy. Based on a detailed understanding of the immune
events occurring during VL, one may envision multiple
points at which immunotherapeutics may intersect the in-
fection and improve the immune response to the parasite.
Some immunotherapeutic strategies have already been
employed in experimental models as well as human pa-
tients with variable degrees of success. Early work consisted
in the administration of type I cytokines, such as IFN-γ and
Il-12 [160, 161], which carries the risk of inducing excessive
immunopathology. As an alternative, blocking the action of
immune-suppressive factors should allow restoration of im-
mune function in a more controlled manner. IL-10 block-
ade, in particular, has obtained remarkable success in
lowering parasite loads, when combined with conventional
treatment, in multiple studies in mice and splenocytes from
human patients [162].
In the past few years, and following the advances in
our understanding of the fundamental immunology of
VL, new immunotherapeutic approaches have been pro-
posed. As discussed above, blocking inhibitory receptors
with the aim of reverting T cell exhaustion has obtained
limited success, possibly because we still do not com-
pletely understand the factors governing T cell exhaus-
tion during VL. Nevertheless, reverting T cell exhaustion
has enjoyed a remarkable success in the treatment of
viral infections and cancer [125]. As such, efforts should
continue to elucidate the role of additional inhibitory re-
ceptors and suppressive cytokines in T cell exhaustion
during VL. The remodelling of lymphoid structures in
the spleen during VL represents an additional target for
immunotherapeutics, as restoration of normal lymphoid
architecture may potentially improve immune function.
Indeed, a study in mice demonstrated that the adminis-
tration of an anti-angiogenic drug prevents splenic vas-
cular remodelling and loss of lymphoid architecture
during VL. As a result, the numbers of IFN-γ-producing
CD4 T cells augmented and the efficacy of antimonial
therapy improved drastically [128]. Finally, as discussed
before, administration of neutralizing or otherwise pro-
tective antibodies should not be discarded as a future
potential immunotherapeutic approach for VL, although
this strategy has not yet been tested by researchers, pos-
sibly because we still do not know whether such anti-
bodies can be produced during VL. Ultimately, effective
and long-lasting control of VL will depend on the devel-
opment of a human vaccine. Unfortunately, despite the
remarkable progress obtained in identifying new im-
munogenic parasite antigens and increasingly powerful
adjuvants, the goal of controlling VL through vaccin-
ation remains a formidable challenge [163]. Such lack of
success results, at least in part, from the incomplete
knowledge on the memory T cell subsets that vaccin-
ation should induce in order to confer protection. In this
respect, VL vaccinology may profit from recent advances
made in cutaneous models of leishmaniasis. Previous
work identified circulating subsets of effector (TEM)
and central memory (TCM) T cells generated in mice
that clear their primary cutaneous infections and that,
when transferred to naïve hosts, could confer partial
protection [164, 165]. More recently, a skin-resident
CD4 T cell memory subset, similarly generated in mice
who resolved their primary infections, was shown to
rapidly produce IFN-γ at the site of secondary challenge
and boost the recruitment circulating T cell memory
subsets. The simultaneous transfer of both skin-resident
and circulating memory T cells to naïve mice conferred
complete protection to L. major infection [166].
Whether skin-resident memory T cells can be generated
and confer protection during visceral Leishmania infec-
tion remains unknown. Nevertheless, a vaccine approach
capable of constraining the visceralizing parasites to the
skin holds much promise as it would block colonization
of the viscera, where these species are perfectly adapted
for survival and subversion of the immune response.
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